Covid-19's Lasting Effects on Health Care
Anne Michaud, Xavier Cousens
Covid-19 will certainly change many aspects of drug approval and the overall regulatory process for biomedical product innovation—first and foremost, new and stronger emphasis on partnership and collaboration across sectors, across disciplines, across borders.
There will be greater clinical-trial innovation in terms of design infrastructure and some of the tools for doing clinical trials. This includes opportunities to integrate digital technologies, such as telemedicine, and hopefully also shine a brighter light on the importance of diversity in clinical trials—making sure that trial participation looks like those who are suffering from the disease and at risk for the disease.
I would like to see a stronger alignment on, what are the unmet public-health and medical-care needs? Certainly for whatever the next emerging infectious-disease threat might be. But there are many other areas of our current set of disease challenges—including chronic disease, diabetes and obesity, and opioid addiction. So can we do both: Work together in new ways, and also create new incentives to drive innovation to develop products that are truly needed, but where the market may not drive that innovation and product development adequately?
With the economy as it is, there will be fewer resources [and greater need for patient care]. My guess is resources will need to be more efficiently used.
https://www.msn.com/en-us/health/medical/covid-19s-lasting-effects-on-health-care/ar-BB18JWrw?li=BBnb7Kz&ocid=DELLDHP